Clinical trial
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and…
NCT00133224 · Cell Genesys, Industry · Terminated
Key facts
| NCT number | NCT00133224 |
|---|---|
| Title | Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients |
| Official title | A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain |
| Lead sponsor | Cell Genesys, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone) |
| Enrollment | 408 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Aug 23, 2005 |
| Last update posted | Sep 23, 2008 |
| Countries | Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: